{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:11:11Z","timestamp":1790791871547,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background and Aims:<\/jats:bold> It\u2019s reported that bone morphogenetic protein 9 (BMP9) played an important role in lipid and glucose metabolism, but the role of BMP9 in nonalcoholic fatty liver disease (NAFLD) is unclear. Here, we evaluated the therapeutic efficacy of recombined BMP9 in NAFLD mice and investigated the potential mechanism.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The effects of recombinant BMP9 on NAFLD were assessed in HFD-induced NAFLD mice. C57BL\/6 mice were administrated with high-fat diet (HFD) for 12 weeks. In the last 4 weeks, mice were treated with PBS or recombined BMP9 once daily. Insulin sensitivity was evaluated by glucose tolerance test (GTT) and insulin tolerance test (ITT) at the end of the 12th week. Then NAFLD related indicators were assessed by a variety of biological methods, including histology, western blotting, real-time PCR, RNA-seq and assay for transposase-accessible chromatin using sequencing (ATAC-seq) analyses.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> BMP9 reduced obesity, improved glucose metabolism, alleviated hepatic steatosis and decreased liver macrophages infiltration in HFD mice. RNA-seq showed that Cers6, Cidea, Fabp4 involved in lipid and glucose metabolism and Fos, Ccl2, Tlr1 involved in inflammatory response downregulated significantly after BMP9 treatment in HFD mouse liver. ATAC-seq showed that chromatin accessibility on promoters of Cers6, Fabp4, Ccl2 and Fos decreased after BMP9 treatment in HFD mouse liver. KEGG pathway analysis of dysregulated genes in RNA-seq and integration of RNA-seq and ATAC-seq showed that TNF signaling pathway and Toll-like receptor signaling pathway decreased in BMP9 treated HFD mouse liver.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our data revealed that BMP9 might alleviate NAFLD via improving glucose and lipid metabolism, decreasing inflammatory response and reshaping chromatin accessibility in HFD mouse liver. BMP9 downregulate genes related to lipid metabolism, glucose metabolism and inflammation expression, at least partially via decreasing promoter chromatin accessibility of Cers6, Fabp4, Fos and Tlr1. BMP9 may also reduce the expression of liver Ccl2, thereby changing the number or composition of liver macrophages, and ultimately reducing liver inflammation. The effect of BMP9 on NAFLD might be all-round, and not limit to lipid and glucose metabolism. Therefore, the underlying mechanism needs to be studied in detail further.<\/jats:p>","DOI":"10.3389\/fphar.2020.605967","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T20:53:22Z","timestamp":1612299202000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["The Role of Bone Morphogenetic Protein 9 in Nonalcoholic Fatty Liver Disease in Mice"],"prefix":"10.3389","volume":"11","author":[{"given":"Qin-Juan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Yan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Lu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Kai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Lai","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8162421","DOI":"10.1155\/2017\/8162421","article-title":"The role of tissue macrophage-mediated inflammation on NAFLD pathogenesis and its clinical implications","volume":"2017","author":"Alisi","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.jhep.2011.10.027","article-title":"Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace","volume":"56","author":"Baffy","year":"2012","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"20656","DOI":"10.3390\/ijms151120656","article-title":"Potential roles of BMP9 in liver fibrosis","volume":"15","author":"Bi","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/gutjnl-2016-313314","article-title":"BMP-9 interferes with liver regeneration and promotes liver fibrosis","volume":"66","author":"Breitkopf-Heinlein","year":"2017","journal-title":"Gut"},{"key":"B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/0471142727","article-title":"ATAC-seq: a method for assaying chromatin accessibility genome-wide","volume":"109","author":"Buenrostro","year":"2015","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"6326","DOI":"10.1210\/en.2008-0655","article-title":"Modulation of bone morphogenetic protein-9 expression and processing by insulin, glucose, and glucocorticoids: possible candidate for hepatic insulin-sensitizing substance","volume":"149","author":"Caperuto","year":"2008","journal-title":"Endocrinology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/nbt795","article-title":"An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis","volume":"21","author":"Chen","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab. Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4137\/CMC.S17067","article-title":"Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases","volume":"8","author":"Furuhashi","year":"2014","journal-title":"Clin. Med. Insights Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/nature05844","article-title":"Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2","volume":"447","author":"Furuhashi","year":"2007","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/path.5170","article-title":"Bone morphogenetic protein receptor signal transduction in human disease","volume":"247","author":"Gomez-Puerto","year":"2019","journal-title":"J. Pathol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.cell.2019.05.008","article-title":"CerS6-derived sphingolipids interact with mff and promote mitochondrial fragmentation in obesity","volume":"177","author":"Hammerschmidt","year":"2019","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.3390\/ijms15045199","article-title":"Potential roles of bone morphogenetic protein (BMP)-9 in human liver diseases","volume":"15","author":"Herrera","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1136\/gutjnl-2018-317543","article-title":"Role of BMP-9 in human liver disease","volume":"68","author":"John","year":"2019","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0340-1","article-title":"Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases","volume":"51","author":"Kim","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1016\/j.biomaterials.2013.12.063","article-title":"BMP-9 as a potent brown adipogenic inducer with anti-obesity capacity","volume":"35","author":"Kuo","year":"2014","journal-title":"Biomaterials"},{"key":"B19","doi-asserted-by":"publisher","first-page":"23557","DOI":"10.1074\/jbc.M114.581439","article-title":"Open chromatin profiling in mice livers reveals unique chromatin variations induced by high fat diet","volume":"289","author":"Leung","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.bbadis.2017.12.008","article-title":"Targeting secreted cytokine BMP9 gates the attenuation of hepatic fibrosis","volume":"1864","author":"Li","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jhep.2020.02.025","article-title":"Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis","volume":"73","author":"Liu","year":"2020","journal-title":"J. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"17937","DOI":"10.1074\/jbc.275.24.17937","article-title":"Bone morphogenetic protein-9. An autocrine\/paracrine cytokine in the liver","volume":"275","author":"Miller","year":"2000","journal-title":"J. Biol. Chem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.cytogfr.2009.10.019","article-title":"Emerging role of bone morphogenetic proteins in adipogenesis and energy metabolism","volume":"20","author":"Schulz","year":"2009","journal-title":"Cytok. Growth Factor Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature11243","article-title":"A map of the cis-regulatory sequences in the mouse genome","volume":"488","author":"Shen","year":"2012","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1210\/endo.136.10.7664647","article-title":"Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation","volume":"136","author":"Song","year":"1995","journal-title":"Endocrinology"},{"key":"B26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/bj3400425","article-title":"Expression of the rat liver carnitine palmitoyltransferase I (CPT-Ialpha) gene is regulated by Sp1 and nuclear factor Y: chromosomal localization and promoter characterization","volume":"340","author":"Steffen","year":"1999","journal-title":"Biochem. J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.cell.2013.07.020","article-title":"Developmental fate and cellular maturity encoded in human regulatory DNA landscapes","volume":"154","author":"Stergachis","year":"2013","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000282086","article-title":"Pathology and biopsy assessment of non-alcoholic fatty liver disease","volume":"28","author":"Straub","year":"2010","journal-title":"Dig. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"20704","DOI":"10.3390\/ijms141020704","article-title":"Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)","volume":"14","author":"Takaki","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/MCO.0000000000000031","article-title":"Fatty acid binding proteins: tissue-specific functions in health and disease","volume":"17","author":"Thumser","year":"2014","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.drudis.2006.03.016","article-title":"Bone morphogenetic proteins and growth differentiation factors as drug targets in cardiovascular and metabolic disease","volume":"11","author":"Tobin","year":"2006","journal-title":"Drug Discov. Today"},{"key":"B32","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/nature18606","article-title":"The landscape of accessible chromatin in mammalian preimplantation embryos","volume":"534","author":"Wu","year":"2016","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"10077","DOI":"10.1096\/fj.201802544RR","article-title":"Role of bone morphogenetic protein-9 in the regulation of glucose and lipid metabolism","volume":"33","author":"Yang","year":"2019","journal-title":"Faseb. J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hep.25611","article-title":"Cidea promotes hepatic steatosis by sensing dietary fatty acids","volume":"56","author":"Zhou","year":"2012","journal-title":"Hepatology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.605967\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T20:53:25Z","timestamp":1612299205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2020.605967\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":34,"alternative-id":["10.3389\/fphar.2020.605967"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.605967","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"article-number":"605967"}}